Akoya Biosciences Q4 EPS $(0.47) Misses $(0.31) Estimate, Sales $16.16M Beat $16.05M Estimate
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.31) by 51.61 percent. This is a 88.92 percent increase over losses of $(4.24) per share
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
Morgan Stanley Maintains Overweight on Akoya Biosciences, Lowers Price Target to $20
Morgan Stanley maintains Akoya Biosciences (NASDAQ:AKYA) with a Overweight and lowers the price target from $24 to $20.
Akoya Biosciences Announces Collaboration With PathAI To ‘Combine Spatial Biology with AI-Powered Tools to Facilitate Discovery of Novel Predictive Biomarkers’
Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology, today announced a collaboration to advance the
Akoya Biosciences Q3 EPS $(0.31) Misses $(0.26) Estimate, Sales $13.50M Beat $12.98M Estimate
Akoya Biosciences (NASDAQ:AKYA) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 87.3 percent increase over losses of $(2.44) per share
Earnings Scheduled For November 8, 2021
Companies Reporting Before The Bell
• Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million.
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 7)
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Oct. 6)